Combination chemotherapy of ranimustine, doxorubicine, and dexamethasone for relapsing multiple myeloma--a pilot study.

Abstract

Twenty patients with relapsing myeloma were treated with combination chemotherapy of ranimustine, doxorubicine, and dexamethasone (RAD) between July 1996 and March 2000. Of the 19 evaluable patients, 5 (26.3%) achieved partial response after the first round of RAD therapy and 10 (52.6%) achieved partial response after the second round of RAD therapy. Of 10 evaluable patients who had previously received high-dose dexamethasone therapy including VAD therapy, 2 (20%) achieved partial response after the first round of RAD therapy and 3 (30%) achieved partial response after the second round of RAD therapy. The median survival was 10.5 months and the progression-free survival was 9.3 months. Patients who responded to RAD therapy had a survival rate at 43 months of 59.3%. Toxicity and adverse events during RAD therapy were tolerable. This pilot study demonstrated that RAD therapy is useful for the treatment o frefractory myeloma.

• Authors: Hirokazu Murakami, Arito Yamane, Morio Sawamura, Morio Matsumoto, Kayoko Murayaman, Shunichi Shimano, Takahiro Jinbo, Akihiko Yokohama, Hideki Uchiumi, Hiroshi Handa, Takafumi Matsushima, Norifumi Tsukamoto, Kimio Morita, Masamitsu Karasawa, Hatsue Ogawara, Yoshihisa Nojima
• Journal: Journal of medicine (J Med) Vol. 34 Issue 1-6 Pg. 39-46 ( 2003) ISSN: 0025-7850 [Print] United States
• PMID: 17682310 (Publication Type: Journal Article)

Chemical References

• Nitrosourea Compounds
• Dexamethasone
• Doxorubicin
• ranimustine

Topics

• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Dexamethasone (adverse effects, therapeutic use)
• Doxorubicin (adverse effects, therapeutic use)
• Humans
• Multiple Myeloma (drug therapy, mortality)
• Nitrosourea Compounds (adverse effects, therapeutic use)
• Pilot Projects